Psoriasis MedDRA version: 19.1 Level: PT Classification code 10037153 Term: Psoriasis System Organ Class: 10040785 - Skin and subcutaneous tissue disorders
Conditions
Interventions
Trade Name: Enstilar, kutanskum
Product Code: 55716
Pharmaceutical Form: Cutaneous spray
Other descriptive name: CALCIPOTRIOL MONOHYDRATE
Concentration unit: µg microgram(s)
Concentration type: equal
Sponsors
Odense University Hospital
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Psoriasis patients aged 18-75 years diagnosed with mild-to moderate psoriasis. Patients need to have a smartphone and basic user skills for the smartphone Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range 106 F.1.3 Elderly (>=65 years) yes F.1.3.1 Number of subjects for this age range 28
Exclusion criteria
Exclusion criteria: aged under 18 and above 75 years, severe degrees of psoriasis, i.e. pustular and erythrodermic psoriasis, lack of smartphones and user skills for the smartphone.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Main Objective: Test if an app for smartphones can improve Medical adherence in psoriasis patients;Secondary Objective: Test if improved medical adherence can improve quality of life and reduce severity of disease;Primary end point(s): rate of secondary medical adherence;Timepoint(s) of evaluation of this end point: week 4. | — |
Secondary
| Measure | Time frame |
|---|---|
| Secondary end point(s): DLQI (dermatology life quality index) and LS-GPA (lattice-system physician global assessment);Timepoint(s) of evaluation of this end point: baseline, week 4, week 8 and week 26 | — |
Countries
Denmark
Contacts
Public ContactMathias Tiedemann Svendsen
Odense University Hospital
Outcome results
None listed